Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing

English version České info

Background:
Seven of 15 clinical trial participants treated with a nucleoside analogue (fialuridine [FIAU]) developed acute liver failure. Five treated participants died, and two required a liver transplant. Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans. Therefore, we investigated whether FIAU-induced liver toxicity could be detected in chimeric TK-NOG mice with humanized livers.

Methods and Findings:
Control and chimeric TK-NOG mice with humanized livers were treated orally with FIAU 400, 100, 25, or 2.5 mg/kg/d. The response to drug treatment was evaluated by measuring plasma lactate and liver enzymes, by assessing liver histology, and by electron microscopy. After treatment with FIAU 400 mg/kg/d for 4 d, chimeric mice developed clinical and serologic evidence of liver failure and lactic acidosis. Analysis of liver tissue revealed steatosis in regions with human, but not mouse, hepatocytes. Electron micrographs revealed lipid and mitochondrial abnormalities in the human hepatocytes in FIAU-treated chimeric mice. Dose-dependent liver toxicity was detected in chimeric mice treated with FIAU 100, 25, or 2.5 mg/kg/d for 14 d. Liver toxicity did not develop in control mice that were treated with the same FIAU doses for 14 d. In contrast, treatment with another nucleotide analogue (sofosbuvir 440 or 44 mg/kg/d po) for 14 d, which did not cause liver toxicity in human trial participants, did not cause liver toxicity in mice with humanized livers.

Conclusions:
FIAU-induced liver toxicity could be readily detected using chimeric TK-NOG mice with humanized livers, even when the mice were treated with a FIAU dose that was only 10-fold above the dose used in human participants. The clinical features, laboratory abnormalities, liver histology, and ultra-structural changes observed in FIAU-treated chimeric mice mirrored those of FIAU-treated human participants. The use of chimeric mice in preclinical toxicology studies could improve the safety of candidate medications selected for testing in human participants.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing. PLoS Med 11(4): e32767. doi:10.1371/journal.pmed.1001628
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001628

Souhrn

Zdroje

1. McKenzieR, FriedMW, SallieR, ConjeevaramH, Di BisceglieAM, et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333: 1099–1105.

2. LeeEW, LaiY, ZhangH, UnadkatJD (2006) Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. J Biol Chem 281: 16700–16706.

3. Manning FJ, Swartz MN (1995) Review of the fialuridine (FIAU) clinical trials. Washington (District of Columbia): National Academies Press.

4. NelsonDR, ZeuzemS, AndreoneP, FerenciP, HerringR, et al. (2012) Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 11: 15–31.

5. LawitzE, MangiaA, WylesD, Rodriguez-TorresM, HassaneinT, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878–1887.

6. JacobsonIM, GordonSC, KowdleyKV, YoshidaEM, Rodriguez-TorresM, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867–1877.

7. PockrosPJ, JensenD, TsaiN, TaylorR, RamjiA, et al. (2013) JUMP-C: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 58: 514–523.

8. PeltzG (2013) Can ‘humanized’ mice improve drug development in the 21st century? Trends Pharmacol Sci 34: 255–260.

9. HasegawaM, KawaiK, MitsuiT, TaniguchiK, MonnaiM, et al. (2011) The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405: 405–410.

10. ItoM, HiramatsuH, KobayashiK, SuzueK, KawahataM, et al. (2002) NOD/SCID/gamma c null mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175–3182.

11. NishimuraT, HuY, WuM, PhamE, SuemizuH, et al. (2013) Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 344: 388–398.

12. HuY, WuM, NishimuraT, ZhengM, PeltzG (2013) Human pharmacogenetic analysis in chimeric mice with ‘humanized livers’. Pharmacogenet Genomics 23: 78–83.

13. XuD, NishimuraT, ZhengM, WooM, SuH, et al. (2013) Enabling autologous human liver regeneration with differentiated adipocyte stem cells. Cell Transplant E-pub ahead of print. doi:10.3727/096368913X673432

14. KilkennyC, BrowneWJ, CuthillIC, EmersonM, AltmanDG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412.

15. BartlettMS (1937) Properties of sufficiency and statistical tests. Proc R Soc Lond A Math Phys Sci 160: 268–282.

16. SmithDA, ObachRS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22: 267–279.

17. GuengerichFP, MacDonaldJS (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 20: 344–369.

18. FattingerK, FunkC, PantzeM, WeberC, ReichenJ, et al. (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223–231.